| Name | BT2 |
| Description | BT2, a BCKDC kinase (BDK) inhibitor, exhibits an IC50 of 3.19 μM and functions as a potent, selective Mcl-1 inhibitor with a Ki value of 59 μM. Its interaction with BDK induces helix movements in the N-terminal domain, leading to BDK's dissociation from the branched-chain α-ketoacid dehydrogenase complex (BCKDC). |
| In vivo | BT2 treatment reduces the protein levels of BDK in kidneys and heart. The -fold activation of BCKDC activity in the above tissues correlates with decreased phosphorylation in heart, muscle, and kidney after the long term BT2 treatment. BT2 (20 mg/kg/day; i.p.; daily; for 7 days; C57BL/6J male mice) treatment robustly enhances BCKDC activity in the heart (12.3-fold) compared with the vehicle-treated animals. Less activation is obtained in muscle and kidney at 3.6- and 3.8-fold, respectively [1]. |
| Storage | Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 82.5 mg/mL (333.87 mM), Sonication is recommended.
10% DMSO+90% Saline : < 8.33 mg/mL (33.71 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
10% DMSO+90% Corn oil : 8.33 mg/mL (33.71 mM), Solution.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : < 8.33 mg/mL (33.71 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
10% DMSO+90% (20% SBE-β-CD in Saline) : < 8.33 mg/mL (33.71 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
|
| Keywords | Mcl-1 | Inhibitor | inhibit | BT-2 | BT2 | BT 2 | BDK | Bcl-2 Family |
| Inhibitors Related | Cyanoacetamide | Ascorbyl palmitate | Pendimethalin | Amantadine | Hydralazine hydrochloride | Semaglutide | Estradiol benzoate | Navitoclax | N-Hydroxyphthalimide | Venetoclax | Benzbromarone | Thymoquinone |
| Related Compound Libraries | Cuproptosis Compound Library | Apoptosis Compound Library | Bioactive Compound Library | Hematonosis Compound Library | Post-Translational Modification Compound Library | Inhibitor Library | Mitochondria-Targeted Compound Library | NO PAINS Compound Library | PPI Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
United States
